Personalized Prescription of ACEI/ARBs for Hypertensive COVID-19 Patients

Dimitris Bertsimas(Massachusetts Institute of Technology), Iván J. Núñez‐Gil(Hospital Clínico San Carlos), Carlos Macaya(Universidad Complutense de Madrid), Omid Nohadani, Luca Mingardi(Massachusetts Institute of Technology), Holly Wiberg(Carnegie Mellon University), Agni Orfanoudaki(Massachusetts Institute of Technology), Bartolomeo Stellato(Princeton University), Alison Borenstein(Massachusetts Institute of Technology), Pankaj Sarin(Brigham and Women's Hospital), Dirk Varelmann(Brigham and Women's Hospital), Vicente Estrada(Instituto de Salud Carlos III)

medRxiv

November 4, 2020

10.1101/2020.10.30.20223594

Cited by 2

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

|JAMA|2021|728

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

|The Lancet|2006|343

Altered metabolism of gut microbiota contributes to chronic immune activation in HIV-infected individuals

|Mucosal Immunology|2014|332